Journal ArticleDOI
"Hit the primary": A paradigm shift in the treatment of metastatic prostate cancer?
TLDR
Preclinical data, clinical experience, and challenges in local treatment in de novo metastatic PC are reviewed and discussed, and modern radiation therapy can play a significant role owing to its intrinsic capability to act as a more general immune response modifier.Abstract:
Patients with metastatic prostate cancer (PC) represent a heterogeneous group with survival rates varying between 13 and 75 months. The current standard treatment in this setting is hormonal therapy, with or without docetaxel-based chemotherapy. In the era of individualized medicine, however, maximizing treatment options, especially in long-term surviving patients with limited disease burden, is of capital importance. Emerging data, mainly from retrospective surgical series, show survival benefits in men diagnosed with metastatic PC following definitive therapy for the prostate. Whether the irradiation of primary tumor in a metastatic disease might improve the therapeutic ratio in association with systemic treatments remains investigational. In this scenario, modern radiation therapy (RT) can play a significant role owing to its intrinsic capability to act as a more general immune response modifier, as well as to the potentially better toxicity profile compared to surgery. Preclinical data, clinical experience, and challenges in local treatment in de novo metastatic PC are reviewed and discussed.read more
Citations
More filters
Journal ArticleDOI
Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience.
Gianluca Ingrosso,Fabio Trippa,Ernesto Maranzano,Alessandra Carosi,Elisabetta Ponti,Fabio Arcidiacono,L. Draghini,Luana Di Murro,Andrea Lancia,Riccardo Santoni +9 more
TL;DR: This study demonstrates that SBRT is safe, effective, and minimally invasive in the eradication of limited nodal metastases, yielding an important delay in prescribing ADT.
Journal ArticleDOI
Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.
TL;DR: The presented review of the body of evidence suggests that additional research in molecular biology may help to establish novel treatments for oligometastatic PCa, and liquid biopsies offer a rapid, non-invasive approach whose use is expected to play an important role in routine clinical practice to benefit patients.
Journal ArticleDOI
Opportunistic dose amplification for proton and carbon ion therapy via capture of internally generated thermal neutrons
Mitra Safavi-Naeini,Andrew Chacon,Andrew Chacon,Susanna Guatelli,Daniel Franklin,Keith Bambery,Marie-Claude Gregoire,Marie-Claude Gregoire,Anatoly B. Rosenfeld +8 more
TL;DR: It is demonstrated that a typical proton or carbon ion therapy treatment plan generates an approximately uniform thermal neutron field within the target volume, centred around the beam path, and the proposed method is theoretically feasible and can provide a worthwhile improvement in the dose delivered to the tumour relative to healthy tissue.
Journal ArticleDOI
Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
Eman Mohamed Othman Mosaad,Eman Mohamed Othman Mosaad,Eman Mohamed Othman Mosaad,Karen F. Chambers,Katarzyna Futrega,Katarzyna Futrega,Judith A. Clements,Michael R. Doran +7 more
TL;DR: Stromal cell composition and geometry influences PCa cell migration, growth and drug response, and the Microwell-mesh and microtissues are powerful tools to study these complex 3D interactions.
Journal ArticleDOI
Local Treatment of Metastatic Prostate Cancer: What is the Evidence So Far?
TL;DR: There is growing evidence supporting local treatment in cases of metastatic prostate cancer at diagnosis in the context of a multimodal approach, and it should be kept in mind that most of the existing studies are retrospective.
References
More filters
Journal ArticleDOI
Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis
Alberto Briganti,R. Jeffrey Karnes,Luigi F. Da Pozzo,Cesare Cozzarini,Umberto Capitanio,Andrea Gallina,Nazareno Suardi,Marco Bianchi,Manuela Tutolo,Andrea Salonia,Nadia Di Muzio,Patrizio Rigatti,Francesco Montorsi,Michael L. Blute +13 more
TL;DR: Adjuvant RT plus HT significantly improved CSS and OS of pT2-4 pN1 patients, regardless of the extent of nodal invasion, and reinforces the need for a multimodal approach in the treatment of node-positive prostate cancer.
Journal ArticleDOI
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
Journal ArticleDOI
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987.
TL;DR: The data suggest that in properly selected patients radical prostatectomy, although not curative, can provide excellent palliation of the local lesion with acceptable morbidity and that symptomatic local recurrence of prostatic cancer achieved with radiation therapy is identical to the results in men who were managed expectantly.
Journal ArticleDOI
Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
Ulrike Schick,Sandra Jorcano,Philippe Nouet,Michel Rouzaud,Hansjoerg Vees,Thomas Zilli,Osman Ratib,Damien C. Weber,Raymond Miralbell +8 more
TL;DR: Oligometastatic patients may be successfully treated with short AD and high-dose irradiation to the metastatic lesions and such a treatment strategy may hypothetically succeed to prolong the failure-free interval between two consecutive AD courses.
Journal ArticleDOI
Intensity-modulated Radiotherapy in the Treatment of Prostate Cancer
TL;DR: Providing that avoidance of acute adverse effects associated with radiation is an outcome of interest, then IMRT is recommended over tangential radiotherapy after breast-conserving surgery, based on a review of six published reports including 2012 patients.